Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CDXC

CDXC - ChromaDex Corp Stock Price, Fair Value and News

$6.25+0.02 (+0.32%)
Market Closed

64/100

CDXC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

64/100

CDXC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.77

Target 3M

$6.19

Target 6M

$6.38

CDXC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDXC Price Action

Last 7 days

-2.9%

Last 30 days

-9.1%

Last 90 days

-20.6%

Trailing 12 Months

0.5%

CDXC RSI Chart

CDXC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDXC Valuation

Market Cap

498.8M

Price/Earnings (Trailing)

24.42

Price/Sales (Trailing)

4

EV/EBITDA

19.86

Price/Free Cashflow

23.34

CDXC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.77

Target 3M

$6.19

Target 6M

$6.38

CDXC Fundamentals

CDXC Revenue

Revenue (TTM)

124.7M

Rev. Growth (Yr)

32.86%

Rev. Growth (Qtr)

9.22%

CDXC Earnings

Earnings (TTM)

20.4M

Earnings Growth (Yr)

143.77%

Earnings Growth (Qtr)

26.85%

CDXC Profitability

Operating Margin

63.89%

EBT Margin

17.04%

Return on Equity

28.91%

Return on Assets

20.82%

Free Cashflow Yield

4.29%

CDXC Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

0.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025107.9M116.3M124.7M0
202483.2M85.6M91.7M99.6M
202377.3M80.9M83.4M83.6M
202270.0M69.1M68.8M72.0M
202159.6M62.0M65.1M67.4M
202050.6M54.8M56.9M59.3M
201935.0M38.3M42.3M46.3M
201824.4M28.0M30.0M31.6M
201719.2M16.0M18.1M21.2M
201622.6M23.9M21.6M21.7M
201517.5M19.7M21.9M22.0M
201410.9M12.0M13.5M15.3M
201312.2M12.2M11.3M10.2M
20127.4M8.1M9.9M11.6M
20117.7M7.8M8.0M8.1M
20100007.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About ChromaDex Corp

CDXC
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
 CEO
 WEBSITEchromadex.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES113

ChromaDex Corp Frequently Asked Questions

CDXC is the stock ticker symbol of ChromaDex Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of ChromaDex Corp is 498.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CDXC's fair value in chart for subscribers.

The fair value guage provides a quick view whether CDXC is over valued or under valued. Whether ChromaDex Corp is cheap or expensive depends on the assumptions which impact ChromaDex Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXC.

As of Tue Jan 27 2026, CDXC's PE ratio (Price to Earnings) is 24.42 and Price to Sales (PS) ratio is 4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ChromaDex Corp has provided 0.044 (multiply by 100 for percentage) rate of return.